Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
US phase 3 ASTRA (NCT07368959) will enroll across ~12 sites, randomizing patients to a single intracameral administration of ...
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery ...
Aurion Biotech, Inc. ("Aurion Biotech"), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced ...
Far more than a superficial epithelial problem, corneal melt is a progressive ulceration of corneal stromal tissue that can compromise the structural integrity of the eye. Corneal melt often precedes ...
IL10 secretion accelerated corneal wound healing in mice, and IL10 receptor blockade abrogated benefit, supporting a ...
Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...
Krystal Biotech, Inc. has initiated its Phase 3 clinical trial, named IOLITE, to evaluate KB803, a gene therapy designed to treat and prevent corneal abrasions in patients with dystrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results